Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Strengthening through Wellness: Individual Preparation Achievement - 2Novo Nordisk cuts Wegovy price in South Africa for a second time
- 37 Extraordinary Efficiency Applications for Experts
- 4All the ways Marjorie Taylor Greene has shifted her approach lately — and why Trump is 'surprised at her'
- 54 astronauts are en route home from ISS after medical issue forces early exit
- The Most recent Microsoft Surface Star PC: Ideal for Top of the line Planning and Gaming Needs
- Russian billionaire says 12-hour days and 6-day workweeks could help save the economy
- Paraplegic engineer becomes the first wheelchair user to blast into space
- Israel violated ceasefire with Hezbollah more than 10,000 times, UNIFIL claims
- An Aide On Upgrading Your FICO rating
- 4 injured in shooting at North Carolina tree lighting ceremony
- Equality requires universal draft, participation in economy and workforce, MK Liberman says
- ‘Aid for Ukraine’ pierogi fundraiser event
- 2026 Golden Globes live updates: Red carpet arrivals will kick off the night; Nikki Glaser set to host
